CW Advisors LLC Invests $576,000 in Insmed, Inc. $INSM

CW Advisors LLC bought a new stake in Insmed, Inc. (NASDAQ:INSM) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,720 shares of the biopharmaceutical company’s stock, valued at approximately $576,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. First Horizon Advisors Inc. increased its holdings in Insmed by 24.8% in the 2nd quarter. First Horizon Advisors Inc. now owns 936 shares of the biopharmaceutical company’s stock valued at $94,000 after buying an additional 186 shares during the period. ORG Partners LLC boosted its position in shares of Insmed by 220.2% during the 2nd quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 196 shares in the last quarter. Coldstream Capital Management Inc. increased its stake in Insmed by 5.2% in the second quarter. Coldstream Capital Management Inc. now owns 4,975 shares of the biopharmaceutical company’s stock valued at $501,000 after acquiring an additional 244 shares during the period. Hilltop National Bank acquired a new position in Insmed in the second quarter worth about $28,000. Finally, Hsbc Holdings PLC raised its position in Insmed by 1.5% in the first quarter. Hsbc Holdings PLC now owns 21,423 shares of the biopharmaceutical company’s stock worth $1,613,000 after purchasing an additional 315 shares in the last quarter.

Insmed Stock Performance

Insmed stock opened at $194.17 on Wednesday. The stock has a 50-day simple moving average of $182.60 and a 200 day simple moving average of $137.24. The stock has a market capitalization of $41.41 billion, a price-to-earnings ratio of -31.37 and a beta of 1.01. The company has a quick ratio of 4.34, a current ratio of 4.63 and a debt-to-equity ratio of 0.59. Insmed, Inc. has a 12-month low of $60.40 and a 12-month high of $212.75.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.40). Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The company had revenue of $142.34 million during the quarter, compared to analyst estimates of $114.33 million. During the same quarter in the previous year, the business posted ($1.27) EPS. The company’s revenue was up 52.4% compared to the same quarter last year. On average, research analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Insider Transactions at Insmed

In other Insmed news, Director Elizabeth M. Anderson sold 10,000 shares of the stock in a transaction on Friday, November 14th. The stock was sold at an average price of $195.87, for a total value of $1,958,700.00. Following the transaction, the director directly owned 63,729 shares in the company, valued at approximately $12,482,599.23. This trade represents a 13.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Melvin Md Sharoky sold 10,000 shares of Insmed stock in a transaction on Friday, September 12th. The shares were sold at an average price of $145.39, for a total value of $1,453,900.00. Following the completion of the sale, the director directly owned 262,675 shares of the company’s stock, valued at $38,190,318.25. This trade represents a 3.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 233,650 shares of company stock worth $41,063,785 over the last ninety days. 3.00% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on INSM shares. Jefferies Financial Group upped their price objective on Insmed from $129.00 to $148.00 and gave the company a “buy” rating in a research note on Wednesday, August 13th. TD Cowen upped their price target on Insmed from $223.00 to $231.00 and gave the company a “buy” rating in a research report on Thursday, November 20th. Guggenheim lifted their price objective on Insmed from $125.00 to $172.00 and gave the company a “buy” rating in a report on Monday, September 8th. Stifel Nicolaus boosted their target price on shares of Insmed from $121.00 to $145.00 and gave the company a “buy” rating in a research note on Thursday, August 14th. Finally, Morgan Stanley upped their target price on shares of Insmed from $126.00 to $144.00 and gave the stock an “equal weight” rating in a report on Thursday, August 21st. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Insmed currently has a consensus rating of “Moderate Buy” and an average price target of $187.89.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.